• Explore /
  • Poster
  • / Clinical validity of CTS5 for estimating risk of late recurrence in unselected, non-trial patients with early ER+ breast cancer.

Clinical validity of CTS5 for estimating risk of late recurrence in unselected, non-trial patients with early ER+ breast cancer.

Abstract Poster

Authors

null

Juliet Richman

Royal Marsden Hospital, London, United Kingdom

Juliet Richman , Alistair E. Ring , Mitchell Dowsett , Ivana Sestak

Sign-In to See More Abstracts, Journal Articles, Posters, Videos and Slides and to Bookmark Your Favorite Content.

Disclaimer

This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org

Poster Details

Meeting

2019 ASCO Annual Meeting

Session Type

Poster Discussion Session

Session Title

Breast Cancer—Local/Regional/Adjuvant

Track

Breast Cancer

Sub Track

Adjuvant Therapy

Citation

J Clin Oncol 37, 2019 (suppl; abstr 514)

DOI

10.1200/JCO.2019.37.15_suppl.514

Abstract #

514

Poster Bd #

6

Abstract Disclosures

Similar Posters

First Author: Yasue Tsuchida

Poster

2016 ASCO Annual Meeting

Optimal endocrine therapy for breast cancer patients 45-50 years of age at diagnosis.

Optimal endocrine therapy for breast cancer patients 45-50 years of age at diagnosis.

First Author: Gwen Dackus

First Author: Bent Ejlertsen

First Author: Pamela Klein